Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer

Table 4

Total dose of oxaliplatin at which 50% of patients developed neuropathy.

	Group A	Group B	Group C	Group D
	(𝑛=11)	(𝑛=14)	(𝑛=21)	(𝑛=44)
Grade ≥1	765	255	340	255
Grade ≥2	Not reached	510	765	670
Grade 3	—	850	—	Not reached

Total oxaliplatin doses are shown in mg/m².
Grade ≥1, Grade 1 or worse neuropathy; Grade ≥2, Grade 2 or worse neuropathy;
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.